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Introduction
There is accumulating evidence that many tumor anti-
gens recognized by autologous cytotoxic lymphocytes
are antigenically normal self-constituents [1,2]. Further-
more, immunotherapy of cancer by vaccination with
tumor antigens or transfusion of ex vivo propagated
cytotoxic lymphocytes often leads to the appearance
of autoimmunity because of antigenic cross-reactions
between tumor antigens and normal tissue antigens
[3,4].
T cells were initially subdivided into two broad
classes, i.e. helper T cells and cytolytic/suppressor T cells,
depending on the expression pattern of certain cell
surface molecules. T cells bearing CD4 molecules (Lyt
1+2−3− in mice in early days) were classified as T helper
cells, whereas CD8+ T cells (Lyt 2+ in mice in early
days) were classified as cytolytic/suppressor T cells.
Thus, suppressor T cells were initially thought to be
mostly CD8+. North’s group first showed that T cells
bearing the helper phenotype (Lyt 1+2−3−) can function
as suppressor T cells in a mouse tumor model [5,6].
That human CD4+ T cells can also function as “suppres-
sor” or “regulatory” T cells were shortly demonstrated
in the human tumor system [7–9].
Regulatory T cells (previously known as T suppressor
cells) re-emerged as a dominant form of immunologic
tolerance in the mid-1990s, when it was identified that
the transfer of CD4+ T cells depleted of the CD25+
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subset into nu/nu recipient mice induced the develop-
ment of organ-specific autoimmune diseases, which
could be reversed by the subsequent transfer of CD4+
CD25+ T cells [10]. Thymectomy of adult rats and mice
followed by fractionated X-irradiation could also pro-
duce autoimmune disease [11]. Collectively, these data
were strongly suggestive of the existence of a thymically
produced suppressive T cell population, which was
responsible for the establishment and maintenance of
peripheral self-tolerance. These regulatory cells appeared
to migrate out from the thymus at a relatively late stage,
when compared with conventional/autoreactive T cells
(more than 3 days after birth in mice) [12]. CD4+ CD25+
T cells have been associated with cancer [13], autoim-
munity [14], transplantation tolerance [15], and,
most recently, with pregnancy [16]. CD4+ CD25+ T
cells actively contribute to the maintenance of natural
immunologic self-tolerance. Self-tolerance maintained
by natural CD4+ CD25+ T cells may, however, impede
development of tumor immunity by hampering the
generation and activation of tumor-effector T cells rec-
ognizing autologous tumor cells. If this is the case,
reduction of CD4+ CD25+ T cells or attenuation of their
suppressive activity may enhance immune responses to
autologous tumor cells.
Generally speaking, CD4+ CD25+ T cells (TR cells)
possess the ability to suppress immune responses and
can be divided into two types: naturally occurring and
adaptive regulatory cells [17]. Naturally occurring reg-
ulatory cells are generated in the thymus under poorly
understood conditions. Adaptive regulatory cells (also
referred to variously as “Th3” or “Tr1”) are generated
outside of the thymus under specialized activation
conditions [12].
Surface Phenotype and Subsets of
Regulatory T Cells
Initially, CD5 was proposed as a marker for TR cells by
demonstrating that the otherwise normal lymphocytes
depleted of CD5high CD4+ cells elicited autoimmunity
when transferred to athymic nude mice [18]. Unfraction-
ated CD4+ cells (which contain CD5 high expressers)
prevented the induction of autoimmunity when co-
transferred along with the CD5low cells, implying that
TR cells were contained specifically within the CD5high
compartment. Similarly, the CD45RB molecule appears
to divide T cells into two distinct functional subsets:
CD45RBhigh and CD45RBlow cells [19]. The CD45RBhigh
population triggers inflammatory bowel disease when
transferred to lymphopenic mice, by eliciting an im-
munopathologic reaction against normal gut flora,
whereas the CD45RBlow counterpart prevents such dis-
ease induction. To date, the most functionally useful
surface marker for TR cells has proven to be their con-
stitutive expression of the interleukin (IL)-2 receptor 
α-chain (IL-2R), CD25. Approximately, 5–10% of CD4+
peripheral T cells constitutively express CD25 in normal
naïve mice and healthy humans [10,20].
Interestingly, CD25 does not appear to be merely 
a marker for TR cells, but rather reflects an absolute
dependence on IL-2 for their peripheral maintenance
and function. This is dramatically demonstrated by the
loss of TR cells and consequent autoimmunity, which
occurs if IL-2 signaling is perturbed, e.g. in the case of
knock-out mice [21] or antibody blockade [22].
More recently, a number of other cell surface 
molecules have been shown to be associated with TR
cells, which includes CTLA-4 (CD152), αEβ7-integrin
(CD103), glucocorticoid-induced tumor necrosis factor
family receptor (GITR), and neuropilin-1 (a receptor
involved in axon guidance) [23–26]. It should be noted,
however, that no single uniquely expressed cell surface
molecule has, thus far, been identified for TR cells, and
in many cases, relatively specific molecules such as
GITR or CD25 are also upregulated to high levels on
activated non-regulatory T cells as well. This problem
is made especially acute in humans who naturally show
large numbers of activated CD25+ T cells, and, there-
fore, a definitive identification is usually only possible
by sorting the highest CD25+ expressers [27].
There are significant differences in the expression of
CD25 on humans as compared with mouse T cells, and
these differences influence the techniques in isolating
TR cells from human peripheral blood. Fluorescence-
activated cell sorting profiles of T cells from mouse
spleen and human peripheral blood stained with anti-
bodies against CD25 and CD4 are not equivalent. In
the mouse, CD4+ CD25+ T cells are seen as a distinct
population of cells that is easily distinguished from the
CD4+ CD25− cells and comprise approximately 10% of
splenic CD4+ T cells. Thus, the isolation of mouse TR
cells is rather straightforward. In contrast, human CD4+
T cells exhibit a continuous and primarily low expres-
sion of CD25 in which 2–4% express high levels of CD25,
while up to 30% express low levels of CD25. This stain-
ing continuum makes it more difficult to determine
whether all or only a subset of the CD25+ cells should
be included in the CD25 TR population. The analysis
of other cell surface proteins expressed on the surface
of CD4+ CD25high or CD4+ CD25low subsets isolated
from peripheral blood indicates that the CD25high sub-
set is homogenous, as over 95% of the cells express
CD45RO, CD62L, and CD122, and includes the major-
ity of cells that express HLA-DR and the transferring
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receptor (CD71) [20,28]. In contrast, the CD25low
subset contains a more heterogeneous mixture of cells,
as demonstrated by expression of CD45RO (80%),
CD62L (80%) and CD122 (28%).
Moreover, it has long been known that there are
major differences in the proteins expressed by humans
when compared with mouse T cells, most strikingly in
regard to HLA-DR and CD45RA/CD45RO. In contrast
to the studies in the mouse demonstrating high levels
of expression of CD62L and CD38 by CD4+ CD25+
T cells, these same surface markers have not been use-
ful for isolation of human regulatory cells [29,30].
Two populations of Foxp3-expressing regulatory 
T cells have been characterized. One lineage, desig-
nated as natural suppressor cells, arises in the thymus
in a pathway that requires T cell receptor stimulation
by peptide-loaded major histocompatibility class II pro-
teins, IL-2, and CD28, and might be mediated through
dendritic cells associated with Hassall’s corpuscles [31].
The maintenance of these cells after thymic export in-
volves additional IL-2, CD40, and probably transforming
growth factor-β (TGF-β). A second group of regulatory
T cells might be induced in the periphery from Foxp3-
negative CD4+ T cells; prolonged, non-inflammatory
antigen exposure and high local concentrations of
TGF-β promote this conversion [32].
Mechanisms of Suppression by
Regulatory T Cells
The mechanism of suppression by CD4+ CD25+ T cells
is still poorly understood. The most basic feature indi-
cated by in vitro models is that suppression requires
direct cell contact between the CD4+ CD25+ TR cell
and the target T responders. Furthermore, it appears
that human CD4+ CD25+ TR cells must be activated
through their T cell receptors in order to be opera-
tionally suppressive [27]. Another in vitro analysis has
concluded that CD25+ suppressor T cells are anergic,
i.e. they do not proliferate in culture when stimulated
with antibodies to CD3 or antigens unless supple-
mented with high doses of IL-2. In the absence of
exogenous IL-2, stimulated CD25+ T cells suppress the
proliferation of CD4+ as well as CD8+ T cells by a reac-
tion that is independent of IL-10 and TGF-β secretion,
as has been shown with suppressor T cells from IL-10-
and TGF-β-deficient mice, which seem to suppress
effectively [33].
However, others have postulated an essential func-
tion for cell-bound TGF-β on the basis of inhibition of
suppression by antibodies to TGF-β [34]. The suppres-
sion of proliferation requires direct cell contact between
suppressor and suppressed cells, as suppression does
not occur when cells are separated by a permeable mem-
brane. The presence of antigen-presenting cells (APCs)
is not required, as suppression occurs in APC-free cul-
tures. In all cases, the suppression requires activation
of suppressor T cells by T cell receptor ligands or anti-
bodies to CD3. No role has been shown for the surface
molecules GITR, CTLA4, or PD-L1 using currently avail-
able blocking antibodies, as the addition of increasing
numbers of CD4+ CD25+ TR cell causes suppression
even in the presence of these reagents [35,36].
Cytolytic activity has been invoked as a possible
mechanism of suppression. Human CD4+ CD25+
Foxp3-expressing T cells can be activated by a combi-
nation of antibodies to CD3 and CD46 to express
granzyme A and kill activated CD4+ and CD8+ T cells
by a perforin-dependent mechanism in a reaction that
does not involve Fas–Fas ligand binding. Antibodies to
CD18 interfere with the killing, suggesting that CD18
is involved in the interaction of suppressor T cells with
their targets. Antibodies to CD3 and CD46 are superior
to antibodies to CD3 and CD28 in inducing granzyme-
and perforin-mediated killing. It remains to be deter-
mined whether activation by antigen can have similar
consequences [37].
Regulatory T Cell and Cancer Immunity
It is becoming increasingly clear that while T effector
cell “boosting” strategies are capable of raising high
levels of antitumor T cells, tumors often grow despite
such lymphocyte induction. The inability of most cancer
patients to mount an effective immune response can
largely be attributed to tumor evasion strategy. Several
tumor immune evasion mechanisms have been defined
and include: (1) downregulation of major histocom-
patibility complex class I, (2) loss of tumor antigen
expression, (3) downregulation of adhesion/accessory
molecules by tumor and/or APC, (4) induction of anergy
or clonal deletion of responding T cells, (5) changes in
T cell signal transduction molecules, (6) secretion of
immunosuppressive cytokines, and (7) the recruitment
or activation of TR cell [38–40].
It is now clear that many tumor-associated anti-
gens recognized by autologous T cells are normal self-
constituents, and thus, presumably within the remit of
control by self-reactive TR cells. TR cells may even be
actively recruited by tumors as a means of immune
evasion. Because tumor-associated regulatory T cells
express Foxp3 mRNA and protein, it is possible that
these cells traffic to tumors from the thymus, bone
marrow, lymph nodes, and peripheral blood [41]. The
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desirable elimination of tumors by cytotoxic effector 
T cells may thus be impeded by the action of TR cells,
and evidence is accumulating that this, in fact, appears
to be the case [42,43]. The early successful attempts
to deplete CD4+ CD25+ TR cells and, hence, induce
tumor regression involved the systemic administration
of anti-CD25 monoclonal antibody (mAb) prior to
tumor challenge [44–46].
But what is the evidence, other than the simple
presence of TR cells in the peripheral blood of cancer
patients, that they have an impact on immunity against
human cancer? Three observations collectively provide
strong evidence that TR cells do, in fact, ameliorate
immunity against a wide variety of human tumors.
First, the frequency of TR population is increased in the
peripheral blood of cancer patients and/or enriched in
frequency among tumor-infiltrating lymphocytes or
within tumor-draining lymph nodes. Second, an accu-
mulation of TR cells in tumor-associated tissue pre-
dicts poor prognosis or survival. Third, TR cells with
specificity for antigens expressed by human tumors
have recently been identified. Numerous studies in
recent years have found increased frequencies of CD4+
CD25+ T cells with some or all of the features of TR in
the peripheral blood of patients with a wide array of
cancers, including head and neck cancer [47], lung can-
cer [48], gastrointestinal cancers [49], pancreatic and
breast cancer [50], and skin cancer [51].
Moreover, experiments suggest that the simple
elimination of TR cells from splenocyte preparations by
treatment with anti-CD25 mAb results in productive
responses to syngeneic tumors when transferred together
to lymphopenic recipients [45,52,53].
One crucial question regarding human tumors and
the increased frequency of TR cells within tumor micro-
environments is the extent to which they are generated
within, versus recruited to, the tumor microenviron-
ment. One study of patients with ovarian carcinoma
found that tumor cells and infiltrating macrophages
secreted the chemokine CCL22, which was shown to
be chemotactic for TR cells, all of which expressed the
relevant CCR4 receptor [54]. Thus, there is a prece-
dent for recruitment of TR cells to a tumor microenvi-
ronment. In addition to enhanced migration, it is also
possible that the increased number of TR cells within
the tumor microenvironment might represent antigen-
induced expansion of natural TR cells or conversion of
non-regulatory T cells into Foxp3+-induced TR cells,
because many tumors produce high levels of TGF-β
(necessary to induce TR cells in vitro) [55].
Intra tumor infiltration/expansion of CD4+ CD25+
Foxp3+ TR cells also potentially constitutes an immune
evasion mechanism in the murine mesothelioma model.
A strong correlation between tumor size and percentage
of CD4+ CD25+ Foxp3+ TR cells was noted, implicating
that increase in TR cells within the small murine mesothe-
liomas allows the evasion of the host antitumor effector
immune response, thus leading to tumor growth [56].
Therapeutic Scheme Involving the 
Use of Regulatory T Cells
The immune responses to cancer mount two major
systems. The innate response, composed of granulo-
cytes, macrophages, dendritic cells, natural killer cells,
and complements, is rapidly triggered into action, detect-
ing tissue disturbance through a set of germline-encoded
pattern recognition receptors. The adaptive reaction,
consisting of antibody-producing B cells and T lympho-
cytes, is slower to develop but manifests exquisite speci-
ficity and memory [57]. Emerging evidence implicates
a critical role for immune regulatory circuits in attenuat-
ing antitumor immunity. These circuits primarily func-
tion to maintain tolerance to normal tissues, but since
cancer arises from self, antitumor immune responses
are similarly subject to regulation.
As detailed earlier, a large body of data from murine
studies have demonstrated the potent ability of both
natural and adaptive regulatory cells to control immune
response under a wide range of clinically important
conditions (Table).
Currently, it is tempting to speculate that part of
the antitumor efficacy of current cytotoxic treatments
might involve antagonizing regulatory T-cell function;
previous work indicated that cyclophosphamide dis-
rupts immune regulatory circuits [58], and thus, patients
with weak regulatory T-cell but strong CD8+ T-cell
reactions might respond to this manipulation. Nonethe-
less, robust regulatory T-cell infiltrates will likely require
more potent and specific strategies, and a number of
critical immunoregulatory molecules expressed on the
surface of regulatory T cells may well be suited to this
purpose. Indeed, initial clinical testing of a fully human
monoclonal antibody that blocks CTLA-4 has already
established the ability of this scheme to effectuate sub-
stantial tumor destruction, although at the expense of
some autoimmunity and potential severe side effects
(e.g. enterocolitis) [59].
Another strategy is using anti-CD25 mAb. Anti-
CD4 mAb has been administered systemically or intra
tumorally to treat different tumor cell lines [44–46,56].
Surprisingly, intra tumoral delivery of anti-CD25 mAb
is potentially feasible. This treatment regime is in line
with the current thinking that TR cells are active at the
site of immune regulation, and attempts to modulate
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the effects of these TR cells should be targeted to these
sites. Moreover, intratumoral treatment may avoid
potential side effects incurred by systemic depletion of
TR cells using systemic delivery of anti-CD25 mAb.
Current tumor antigen vaccination strategies have
begun to incorporate strategies that combine depletion
of TR cells followed by tumor vaccination, to foster
better expansion and/or effector function of vaccine-
induced tumor immunity. In this regard, IL-2 diphtheria
toxin fusion protein (ONTAK) has shown efficacy in the
treatment of non-Hodgkin’s lymphoma and cutaneous
T cell lymphoma [60]. Moreover, signaling directed
through Toll-like receptor 8 via a CpG motif can reverse
TR cells function in vitro and in vivo [61], further demon-
strating that it might be feasible to manipulate TR cells
activity to enhance the efficacy of cancer vaccines. This
evidence also has implications for the potential addi-
tional effectiveness of DNA-based vaccines, because they
are likely to contain CpG motifs [62,63].
Conclusion
It is now clear that TR cells actively hinder tumor
immunity in cancer patients. Emerging data indicate
that TR cells might be generated to the same tumor-
associated (self) antigens that comprise many candi-
date cancer vaccines. Removal of TR cells lead to the
activation of not only tumor-specific CD8+ cytotoxic
T lymphocytes, but also, presumably, tumor-specific
CD4+ helper T cells. Using this strategy can help devise
a novel immunotherapy for cancer in humans or make
the current immunotherapies more effective, e.g. by
cytokine gene transduction in tumor cells, DNA vacci-
nation, vaccination with tumor antigens/peptides, or
tumor antigen-pulsed dendritic cells.
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